irinotecan

The drug is used for the treatment of patients with advanced colorectal cancer. It may be used as monotherapy or in combination with other medicinal products (e.g., 5-fluorouracil, folinic acid, cetuximab, bevacizumab, or capecitabine).

Form: concentrate for infusion solution

ATC: L01CE02

Manufacturer: Actavis Italia S.p.A.

The drug is used to treat patients with metastatic colorectal cancer. It may be used as monotherapy or in combination with other drugs (e.g., 5-fluorouracil, folinic acid, bevacizumab, cetuximab, or capecitabine).

Form: concentrate for infusion solution

ATC: L01CE02

Manufacturer: Accord Healthcare Polska Sp. z o.o. Importer's Warehouse (Responsible for batch release)

The drug is used to treat advanced colorectal cancer. It may be used either alone or in combination with other drugs (e.g., 5-fluorouracil, folinic acid, cetuximab, bevacizumab, or capecitabine) depending on the stage of the disease and previous treatment.

Form: concentrate for infusion solution

ATC: L01CE02

Manufacturer: AkVida GmbH (batch control and batch release; bulk manufacturing, primary and secondary packaging, batch control)

The drug is used to treat patients with metastatic colorectal cancer. It may be prescribed as monotherapy or in combination with other drugs (e.g., 5-fluorouracil, folinic acid, cetuximab, bevacizumab, or capecitabine) depending on the stage of the disease and previous treatment.

Form: concentrate for infusion solution

ATC: L01XX19*

Manufacturer: Thymoorganon Pharmazie GmbH

The drug is intended for the treatment of advanced colorectal cancer. It is used both in combination with other drugs (5-fluorouracil, folinic acid, bevacizumab, cetuximab, or capecitabine) and as monotherapy if previous treatment has been ineffective.

Form: concentrate for infusion solution

ATC: L01CE02

Manufacturer: Medac Gesellschaft für klinische Spezialpräparate mbH (Manufacturer responsible for primary packaging labelling, secondary packaging, application of protective film (optional), batch control/testing and batch release)

The drug is used to treat patients with metastatic colorectal cancer. It may be used as monotherapy or in combination with other drugs (for example, 5-fluorouracil, folinic acid, bevacizumab, cetuximab, or capecitabine).

Form: concentrate for infusion solution

ATC: L01XX19

Manufacturer: Shilpa Medicare Limited (Full production cycle; Quality control and stability testing (physical and chemical tests))

The drug is used to treat patients with metastatic colorectal cancer. It may be prescribed as monotherapy or in combination with other drugs (e.g., 5-fluorouracil, folinic acid, bevacizumab, cetuximab, or capecitabine) depending on the stage and previous treatment.

Form: concentrate for infusion solution

ATC: L01CE02

Manufacturer: Venus Remedies Limited

The drug is used for the treatment of patients with metastatic colorectal cancer. It may be used both in combination with other drugs (e.g., 5-fluorouracil, folinic acid, bevacizumab, cetuximab, or capecitabine) and as monotherapy if previous treatment has been ineffective.

Form: concentrate for infusion solution

ATC: L01XX19

Manufacturer: Actavis Italia S.p.A.

The drug is used for the treatment of metastatic colorectal cancer. It may be used either as monotherapy or in combination with other drugs (e.g., 5-fluorouracil, folinic acid, cetuximab, bevacizumab, or capecitabine) depending on the treatment regimen and the patient's previous experience.

Form: concentrate for infusion solution

ATC: L01CE02

Manufacturer: Hetero Labs Limited

The drug is used to treat patients with advanced colorectal cancer. It may be used either as monotherapy or in combination with other medicinal products (e.g., 5-fluorouracil, folinic acid, cetuximab, bevacizumab, or capecitabine) depending on the stage of the disease and previous treatment.

Form: concentrate for infusion solution

ATC: L01CE02

Manufacturer: Eugia Pharma Specialities Limited

The drug is used for the treatment of patients with advanced colorectal cancer. It may be used either as monotherapy or in combination with other medicinal products (e.g., 5-fluorouracil, folinic acid, cetuximab, bevacizumab, or capecitabine) depending on the stage of the disease and previous treatment.

Form: solution for injection

ATC: L01XX19

Manufacturer: Venus Remedies Limited